News Daily News Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER Michael O'Riordan December 12, 2025
News Opinion Editor's Corner ESC 2025 What’s Going to Be Hot at ESC Congress 2025? Michael O'Riordan August 25, 2025
News Daily News Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab Michael O'Riordan February 05, 2025
News Daily News Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER Michael O'Riordan February 08, 2024
News Daily News No Safety Concerns Seen With Inclisiran in Large ORION Analysis Michael O'Riordan December 06, 2023
News Daily News Aggressive Lipid-Lowering Very Unlikely to Hurt the Brain: AHA Todd Neale September 19, 2023
News Conference News ACC 2023 Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes Michael O'Riordan March 04, 2023
News Conference News ESC 2022 Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE Michael O'Riordan August 31, 2022
News Conference News ACC 2022 PACMAN-AMI: Positive Plaque Changes With Early Alirocumab Use in Acute MI Todd Neale April 03, 2022
News Daily News Nonfatal MI Not a Death Surrogate in Cardiology: Meta-analysis Caitlin E. Cox October 27, 2021
News Conference News ESC 2021 No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER Michael O'Riordan September 02, 2021
News Conference News EAS 2021 For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short Michael O'Riordan June 03, 2021
News Conference News AHA 2020 Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol Michael O'Riordan November 12, 2020
Presentation TCT 2020 TCT 602: Bewildering Pseudoaneurysm: An Odyssey of Cover Stenting Presenter: ROOPESH SINGHAL October 14, 2020
News Daily News FOURIER Surveys Reassure About Cognitive Safety of Evolocumab Todd Neale May 06, 2020
News Daily News Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES Michael O'Riordan May 04, 2020
News Daily News Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes Michael O'Riordan January 14, 2020
News Daily News Most Secondary Prevention Patients Are Eligible for Multiple Drugs Michael O'Riordan January 03, 2020